Cargando…
P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430028/ http://dx.doi.org/10.1097/01.HS9.0000847272.47630.ff |
| _version_ | 1784779632243900416 |
|---|---|
| author | Eyre, T. A. Wang, M. L. Shah, N. N. Alencar, A. J. Gerson, J. N. Patel, M. R. Fakhri, B. Vandenberghe, E. Jurczak, W. Tan, X. N. Lewis, K. L. Fenske, T. Wang, Y. Coombs, C. C. Flinn, I. Lewis, D. Le Gouill, S. Gandhi, M. Chay, C. Palomba, M. L. Woyach, J. A. Pagel, J. M. Lamanna, N. Sharman, J. P. Andorsky, D. J. Cohen, J. B. Barve, M. A. Ghia, P. Yin, M. Zinzani, P. L. Ujjani, C. Koh, Y. Izutsu, K. Lech-Maranda, E. Kherani, J. Tam, C. Sundaram, S. Nair, B. Tsai, D. E. Balbas, M. Mato, A. R. Cheah, C. Y. |
| author_facet | Eyre, T. A. Wang, M. L. Shah, N. N. Alencar, A. J. Gerson, J. N. Patel, M. R. Fakhri, B. Vandenberghe, E. Jurczak, W. Tan, X. N. Lewis, K. L. Fenske, T. Wang, Y. Coombs, C. C. Flinn, I. Lewis, D. Le Gouill, S. Gandhi, M. Chay, C. Palomba, M. L. Woyach, J. A. Pagel, J. M. Lamanna, N. Sharman, J. P. Andorsky, D. J. Cohen, J. B. Barve, M. A. Ghia, P. Yin, M. Zinzani, P. L. Ujjani, C. Koh, Y. Izutsu, K. Lech-Maranda, E. Kherani, J. Tam, C. Sundaram, S. Nair, B. Tsai, D. E. Balbas, M. Mato, A. R. Cheah, C. Y. |
| author_sort | Eyre, T. A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430028 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94300282022-08-31 P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY Eyre, T. A. Wang, M. L. Shah, N. N. Alencar, A. J. Gerson, J. N. Patel, M. R. Fakhri, B. Vandenberghe, E. Jurczak, W. Tan, X. N. Lewis, K. L. Fenske, T. Wang, Y. Coombs, C. C. Flinn, I. Lewis, D. Le Gouill, S. Gandhi, M. Chay, C. Palomba, M. L. Woyach, J. A. Pagel, J. M. Lamanna, N. Sharman, J. P. Andorsky, D. J. Cohen, J. B. Barve, M. A. Ghia, P. Yin, M. Zinzani, P. L. Ujjani, C. Koh, Y. Izutsu, K. Lech-Maranda, E. Kherani, J. Tam, C. Sundaram, S. Nair, B. Tsai, D. E. Balbas, M. Mato, A. R. Cheah, C. Y. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430028/ http://dx.doi.org/10.1097/01.HS9.0000847272.47630.ff Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Eyre, T. A. Wang, M. L. Shah, N. N. Alencar, A. J. Gerson, J. N. Patel, M. R. Fakhri, B. Vandenberghe, E. Jurczak, W. Tan, X. N. Lewis, K. L. Fenske, T. Wang, Y. Coombs, C. C. Flinn, I. Lewis, D. Le Gouill, S. Gandhi, M. Chay, C. Palomba, M. L. Woyach, J. A. Pagel, J. M. Lamanna, N. Sharman, J. P. Andorsky, D. J. Cohen, J. B. Barve, M. A. Ghia, P. Yin, M. Zinzani, P. L. Ujjani, C. Koh, Y. Izutsu, K. Lech-Maranda, E. Kherani, J. Tam, C. Sundaram, S. Nair, B. Tsai, D. E. Balbas, M. Mato, A. R. Cheah, C. Y. P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY |
| title | P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY |
| title_full | P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY |
| title_fullStr | P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY |
| title_full_unstemmed | P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY |
| title_short | P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY |
| title_sort | p1101: pirtobrutinib, a highly selective, non-covalent (reversible) btk inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1/2 bruin study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430028/ http://dx.doi.org/10.1097/01.HS9.0000847272.47630.ff |
| work_keys_str_mv | AT eyreta p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT wangml p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT shahnn p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT alencaraj p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT gersonjn p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT patelmr p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT fakhrib p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT vandenberghee p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT jurczakw p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT tanxn p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT lewiskl p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT fensket p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT wangy p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT coombscc p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT flinni p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT lewisd p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT legouills p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT gandhim p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT chayc p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT palombaml p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT woyachja p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT pageljm p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT lamannan p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT sharmanjp p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT andorskydj p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT cohenjb p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT barvema p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT ghiap p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT yinm p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT zinzanipl p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT ujjanic p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT kohy p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT izutsuk p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT lechmarandae p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT kheranij p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT tamc p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT sundarams p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT nairb p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT tsaide p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT balbasm p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT matoar p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy AT cheahcy p1101pirtobrutinibahighlyselectivenoncovalentreversiblebtkinhibitorinpreviouslytreatedmantlecelllymphomaupdatedresultsfromthephase12bruinstudy |